In Kirby-Bauer disk diffusion, what does a zone of inhibition indicate about the drug–organism combination according to breakpoints?

In Kirby-Bauer disk diffusion, what does a zone of inhibition indicate about the drug–organism combination according to breakpoints?

• A. The zone size alone determines the exact MIC.
• B. The zone size is interpreted against established breakpoints to categorize the organism as susceptible, intermediate, or resistant.
• C. Zone size directly indicates clinical efficacy in vivo.
• D. Zone size has no relation to susceptibility categories.

Answer: (B)

In Kirby-Bauer disk diffusion, the zone of inhibition is interpreted by comparing the measured diameter to standardized breakpoints for each organism–drug pair. Those breakpoints define threshold diameters that categorize the organism as susceptible, intermediate, or resistant. This categorization reflects whether the drug is likely to reach effective concentrations at the infection site under typical dosing. A zone larger than the susceptible breakpoint suggests the drug should work; a zone in the intermediate range indicates possible effectiveness only under specific conditions (such as higher dosages or favorable infection sites); a zone below the resistant breakpoint implies the drug is unlikely to be effective with standard therapy. Breakpoints are established by integrating MIC distributions, pharmacokinetics/pharmacodynamics, and clinical outcomes, and are specific to the organism and drug. Therefore, the zone size serves as a practical surrogate that guides therapy through these categories, rather than giving an exact MIC or guaranteeing in vivo efficacy.

In Kirby-Bauer disk diffusion, the zone of inhibition is interpreted by comparing the measured diameter to standardized breakpoints for each organism–drug pair. Those breakpoints define threshold diameters that categorize the organism as susceptible, intermediate, or resistant. This categorization reflects whether the drug is likely to reach effective concentrations at the infection site under typical dosing. A zone larger than the susceptible breakpoint suggests the drug should work; a zone in the intermediate range indicates possible effectiveness only under specific conditions (such as higher dosages or favorable infection sites); a zone below the resistant breakpoint implies the drug is unlikely to be effective with standard therapy. Breakpoints are established by integrating MIC distributions, pharmacokinetics/pharmacodynamics, and clinical outcomes, and are specific to the organism and drug. Therefore, the zone size serves as a practical surrogate that guides therapy through these categories, rather than giving an exact MIC or guaranteeing in vivo efficacy.